Mutations As Munitions: Neoantigen Vaccines Get a Closer Look As Cancer Treatment

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2016 Feb 5

PMID 26845402

Citations 6

Authors

Alla Katsnelson

Affiliations

Soon will be listed here.

Citing Articles

Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma.

Lin Z, Jiang C, Wang P, Chen Q, Wang B, Fu X Theranostics. 2023; 13(12):4166-4181.

PMID: 37554274 PMC: 10405843. DOI: 10.7150/thno.85843.

Personalized Neoantigen-Pulsed DC Vaccines: Advances in Clinical Applications.

Tang L, Zhang R, Zhang X, Yang L Front Oncol. 2021; 11:701777.

PMID: 34381724 PMC: 8350509. DOI: 10.3389/fonc.2021.701777.

Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development.

Zaidi N, Soban M, Chen F, Kinkead H, Mathew J, Yarchoan M JCI Insight. 2020; 5(17).

PMID: 32879142 PMC: 7526456. DOI: 10.1172/jci.insight.136991.

Immunotherapy in Ovarian Cancer.

Wang W, Liu J, Zou W Surg Oncol Clin N Am. 2019; 28(3):447-464.

PMID: 31079799 PMC: 7017862. DOI: 10.1016/j.soc.2019.02.002.

High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome.

Chong C, Marino F, Pak H, Racle J, Daniel R, Muller M Mol Cell Proteomics. 2017; 17(3):533-548.

PMID: 29242379 PMC: 5836376. DOI: 10.1074/mcp.TIR117.000383.

References

Vetizou M, Pitt J, Daillere R, Lepage P, Waldschmitt N, Flament C . Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015; 350(6264):1079-84. PMC: 4721659. DOI: 10.1126/science.aad1329. View

Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J . Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015; 520(7549):692-6. PMC: 4838069. DOI: 10.1038/nature14426. View

Mandelboim O, Vadai E, Fridkin M, Feldman M, Berke G, Eisenbach L . Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med. 1995; 1(11):1179-83. DOI: 10.1038/nm1195-1179. View

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Tran E, Turcotte S, Gros A, Robbins P, Lu Y, Dudley M . Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014; 344(6184):641-5. PMC: 6686185. DOI: 10.1126/science.1251102. View

Lu Y, Yao X, Li Y, El-Gamil M, Dudley M, Yang J . Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol. 2013; 190(12):6034-42. PMC: 3679246. DOI: 10.4049/jimmunol.1202830. View

Carreno B, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti A . Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015; 348(6236):803-8. PMC: 4549796. DOI: 10.1126/science.aaa3828. View

Sivan A, Corrales L, Hubert N, Williams J, Aquino-Michaels K, Earley Z . Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015; 350(6264):1084-9. PMC: 4873287. DOI: 10.1126/science.aac4255. View

Matsushita H, Vesely M, Koboldt D, Rickert C, Uppaluri R, Magrini V . Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012; 482(7385):400-4. PMC: 3874809. DOI: 10.1038/nature10755. View

10.

van Rooij N, van Buuren M, Philips D, Velds A, Toebes M, Heemskerk B . Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013; 31(32):e439-42. PMC: 3836220. DOI: 10.1200/JCO.2012.47.7521. View

11.

Prehn R, MAIN J . Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957; 18(6):769-78. View

12.

Van Allen E, Miao D, Schilling B, Shukla S, Blank C, Zimmer L . Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015; 350(6257):207-211. PMC: 5054517. DOI: 10.1126/science.aad0095. View

13.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

14.

Castle J, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J . Exploiting the mutanome for tumor vaccination. Cancer Res. 2012; 72(5):1081-91. DOI: 10.1158/0008-5472.CAN-11-3722. View